⌘K
Loading ticker…
As of 2026-08-24, Aptevo Therapeutics Inc (APVO) has a 3-month relative strength percentile of 6 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 27. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.7%, relative volume 5.25×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
APVO is in a stage 4 downtrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -41.6% / -71.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
APVO appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $54K notional.
Held by 1 ETFs · $54K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $54K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APVO Jan avg: -8.08% median: -5.51% win: 25% σ: 11.11% n: 4 2022-04-12 → 2026-07-31 | APVO Feb avg: -3.84% median: -3.57% win: 50% σ: 7.89% n: 4 2022-04-12 → 2026-07-31 | APVO Mar avg: -38.15% median: -39.48% win: 0% σ: 26.89% n: 4 2022-04-12 → 2026-07-31 | APVO Apr avg: -28.12% median: -9.36% win: 20% σ: 40.31% n: 5 2022-04-12 → 2026-07-31 | APVO May avg: -13.04% median: 0.27% win: 60% σ: 25.67% n: 5 2022-04-12 → 2026-07-31 | APVO Jun avg: -26.05% median: -21.83% win: 0% σ: 20.76% n: 5 2022-04-12 → 2026-07-31 | APVO Jul avg: -0.57% median: -7.43% win: 40% σ: 22.73% n: 5 2022-04-12 → 2026-07-31 | APVO Aug avg: -29.95% median: -25.98% win: 0% σ: 23.51% n: 4 2022-04-12 → 2026-07-31 (current) | APVO Sep avg: -25.19% median: -19.56% win: 0% σ: 17.57% n: 4 2022-04-12 → 2026-07-31 | APVO Oct avg: 10.36% median: 3.12% win: 50% σ: 28.04% n: 4 2022-04-12 → 2026-07-31 | APVO Nov avg: -9.32% median: -3.83% win: 50% σ: 17.42% n: 4 2022-04-12 → 2026-07-31 | APVO Dec avg: -37.33% median: -42.03% win: 0% σ: 28.02% n: 4 2022-04-12 → 2026-07-31 |